CRA International CEO Paul Maleh sells over $1m in company stock

CRA International CEO Paul Maleh sold 7,500 shares on June 3, 2026 for $1.03 million under a prearranged 10b5-1 plan, leaving him with 111,050 shares. The sale comes after Q1 2026 revenue rose 10.5% year over year to a record $201 million, but EPS missed estimates at $1.99 versus $2.06. Separately, the stock is down 28% year to date and trading at $145.71 versus analyst targets of $245-$260.

Analysis

CRAI sits in a classic late-cycle consulting setup: revenue can still look healthy while margin quality deteriorates as clients delay discretionary work, push on pricing, or shift mix toward lower-margin projects. That makes the insider sale more useful as a signal of management’s view on near-term multiple expansion than on the business itself — especially because the stock is already discounting a recovery scenario. If earnings keep missing by a few cents while revenue holds up, the market is likely to compress the P/E first, not wait for a fundamental break.

The second-order issue is competitive: weaker public-market perception can actually help larger rivals with stronger balance sheets and broader delivery platforms win share in higher-stakes strategic work. Smaller advisory peers and specialty boutiques may also see spillover if buyers conclude the entire segment is “good revenue, poor conversion” and demand tougher fee terms. The risk is not a collapse in demand; it is a prolonged de-rating over multiple quarters as investors stop paying up for top-line growth that does not convert into EPS.

The contrarian view is that the stock may be over-penalized because insider selling from a 10b5-1 plan is being read as a directional negative when it is more likely a liquidity event. If the company can show even modest margin stabilization next quarter, the gap between current valuation and sell-side targets is large enough to trigger a sharp rerating. But absent an EPS beat, this is a name where the upside case needs proof, not narrative, and that makes the risk/reward unattractive until fundamentals re-accelerate.

Key Decisions for Investors

• Short CRAI outright into the next earnings window: downside skew is better than upside because a modest EPS miss can drive multiple compression faster than revenue growth can support rerating.
• Use puts rather than stock if liquidity is a concern: buy 1-2 month CRAI downside puts around current levels to express a catalyst-driven view with defined risk; target 2-3x premium if margins disappoint again.
• Pair trade: long higher-quality consulting/services names with stronger margin consistency against short CRAI for a relative-value expression on earnings quality over revenue growth.
• If already short, cover 25-50% on any guidance-backed stabilization in margins; this name can re-rate violently on a single quarter if the market regains confidence in EPS conversion.
• If looking to go long, wait for proof: only add after a quarter with EPS beat and stable margins, because the current setup is still a valuation trap until the market sees operating leverage.